Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

134.92 +1.75 (+1.31%)
Official Closing Price Updated: 7:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
42 43 Next >
8 Dividend Aristocrats to Buy Now for a Lifetime of Passive Income
Dividend stocks are a great way to protect against a downturn and these are the cream of the crop. 
Via The Motley Fool
Is This Stock-Split Stock a Buy For 2023?
Don't buy this company's shares for its recent stock split. 
Via The Motley Fool
Better Dividend Stock: AbbVie or Viatris?
These pharmaceutical companies are profitable and offer above-average dividends. 
Via The Motley Fool
2 Unbeatable Dividend Stocks Billionaires Keep Buying in a Bear Market
Some of the world's most successful investors made big bets on these dividend payers recently. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years
Via Benzinga
Could an Investment in AbbVie Give You $10,000 in Annual Dividend Income by Retirement?
This is a stock that rewards long-term investors through continual dividend increases. 
Via The Motley Fool
2 Reasons to Buy Abbott Labs and 1 Reason to Sell
The healthcare company offers growth and value. 
Via The Motley Fool
2 Stocks Down 75% and 26% to Buy Right Now
It's time to go bargain hunting. 
Via The Motley Fool
FDA Outlines Strategy To Review Infant Formula Production Rules
Via Benzinga
Want $10,000 in Annual Dividend Income by Retirement? Here's How Much You Should Invest in AbbVie Today.
This is a stock that rewards long-term investors through continual dividend increases. 
Via The Motley Fool
AbbVie Boosts Its Dividend: Is the Dividend King a Buy?
Shares of the pharmaceutical stock have left the S&P 500 index in the dust so far this year. 
Via The Motley Fool
2 Reasons to Buy AbbVie Stock and 1 Reason to Sell
The pharmaceutical company's golden goose is about to stop laying golden eggs, but that won't be a permanent problem. 
Via The Motley Fool
Want Passive Income in 2023? Buy These Dividend Kings
These stocks offer you a gift: recurrent income just for owning them. 
Via The Motley Fool
7 No-Brainer Blue-Chip Stocks to Buy for 2023 and Beyond
With so many troubles ailing the economy and the broader market, investors should focus on these no-brainer blue-chip stocks to buy. 
Via InvestorPlace
3 Reasons to Buy AbbVie Stock Right Now
The drugmaker has something to offer to all kinds of investors. 
Via The Motley Fool
Here's How Much $1000 Invested In Abbott Laboratories 10 Years Ago Would Be Worth Today
Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 10 years by 1.79% on an annualized basis producing an average annual return of 12.9%. Currently, Abbott Laboratories has a... 
Via Benzinga
Better Buy: Johnson & Johnson vs. Abbott Laboratories
These two healthcare giants are among the safest stocks investors can buy right now. 
Via The Motley Fool
3 Top Healthcare Stocks Defying the Bear Market
These healthcare companies haven't been slowed by macroeconomic conditions. 
Via The Motley Fool
3 Food Processing Dividend Stocks That Could Benefit From Food Shortages Driven By Russia-Ukraine War
With global supply chain shortages impacting nearly every sector of the economy in the past two years, will global food shortages worsen? As the U.S. 
Via Benzinga
Got $1,000? 2 Bear Market Stocks to Jump On Right Now
Regardless of what the market does next, these top stocks have a much longer growth trajectory ahead. 
Via The Motley Fool
Investing $1,000 in the Current Market? Don't Overlook These 2 Winning Dividend Stocks
Just because the stock market is going haywire doesn't mean you have to sit on the sidelines. 
Via The Motley Fool
2 Reasons to Buy DexCom, and 1 Reason to Sell
Do the potential benefits outweigh the risks? 
Via The Motley Fool
Edwards Life Sciences Stock Disaster Could Be Your Bounty
Heart disease equipment maker Edwards Life Sciences (NYSE: EW) stock has fallen (-46%) on the year after a disastrous reaction to its Q3 2022 earnings report. 
Via MarketBeat
Topics Death
Exposures COVID-19 Death
Targeting Autosomal Dominant Polycystic Kidney Disease With Novel Approaches
Approximately 160,000 individuals in the United States are diagnosed with polycystic kidney disease, and the global prevalence of the condition is estimated at between 4 million and 7 million people. 
Via Benzinga
Got $5,000? Buy These 3 Dividend Kings And Hold Them Forever
These healthcare companies should stay relevant for years as they continue to innovate with new products. 
Via The Motley Fool
Is DexCom a Good Healthcare Stock to Buy Now?
After rising about 50% in October, investors want to know if this stock still has any fuel in the tank. 
Via The Motley Fool
3 Dividend-Paying Stocks to Buy in November and Hold Forever
Adding these stocks to your portfolio could lead to a lifetime of passive income. 
Via The Motley Fool
This Groundbreaking Device Just Keeps Winning for Abbott Labs
Its continuous glucose monitor has proven immensely effective in helping type 2 diabetes patients. 
Via The Motley Fool
Intuitive Surgical Stock is Both a Legacy and Next-Gen Play
It’s hard to believe that the da Vinci Surgical System developed by Intuitive Surgical (NASDAQ: ISRG) is turning 22 years old since its U.S. Food and Drug 
Via MarketBeat
Topics Economy
Exposures COVID-19 Interest Rates Supply Chain
NYSE: ABT Investor Notice: Deadline on October 31, 2022 in Lawsuit Against Abbott Laboratories
San Diego, CA -- (SBWIRE) -- 10/31/2022 -- The Shareholders Foundation announced that a deadline is coming up on October 31, 2022 in the lawsuit filed for certain investors of Abbott Laboratories... 
Via SBWire
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.